Brokerages Set Bicara Therapeutics Inc. (NASDAQ:BCAX) PT at $32.25

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have been assigned an average recommendation of “Buy” from the ten analysts that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $32.2513.

A number of analysts have commented on the stock. HC Wainwright cut their price objective on shares of Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating for the company in a report on Friday, August 22nd. Wedbush restated an “outperform” rating and issued a $30.00 price target on shares of Bicara Therapeutics in a research report on Tuesday, August 12th. Finally, Piper Sandler started coverage on Bicara Therapeutics in a report on Monday, August 18th. They issued an “overweight” rating and a $36.00 price target for the company.

Bicara Therapeutics Stock Performance

Shares of BCAX stock opened at $13.87 on Friday. Bicara Therapeutics has a fifty-two week low of $7.80 and a fifty-two week high of $28.09. The stock’s fifty day moving average is $11.45 and its two-hundred day moving average is $11.58. The firm has a market capitalization of $756.75 million and a P/E ratio of -4.38.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Tuesday, August 12th. The company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.04. On average, equities analysts forecast that Bicara Therapeutics will post -2.59 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. XTX Topco Ltd boosted its holdings in Bicara Therapeutics by 4.1% in the 1st quarter. XTX Topco Ltd now owns 28,453 shares of the company’s stock valued at $371,000 after purchasing an additional 1,119 shares during the last quarter. Legal & General Group Plc raised its position in shares of Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after buying an additional 1,233 shares during the period. California State Teachers Retirement System purchased a new stake in shares of Bicara Therapeutics during the 4th quarter valued at approximately $25,000. Ameritas Investment Partners Inc. lifted its holdings in Bicara Therapeutics by 73.0% in the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock valued at $32,000 after acquiring an additional 1,474 shares during the last quarter. Finally, BNP Paribas Financial Markets purchased a new position in Bicara Therapeutics in the fourth quarter worth approximately $32,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.